Publication: First-in-human studies of pharmacokinetics and safety of utreloxastat (PTC857), a novel 15-lipooxygenase inhibitor for the treatment of amyotrophic lateral sclerosis
This first-in-human double-blind, placebo-controlled trial, published in Clinical Pharmacology in Drug Development, investigates the safety and pharmacokinetics (PK) of utreloxastat in healthy participants for the potential treatment of amyotrophic lateral sclerosis (ALS)
Learn more about ALS, a progressive, rare neurodegenerative genetic disease
Review the patient characteristics and the study protocol
Discover utreloxastat, a 15-lipoxygenase (15-LO) inhibitor in development for ALS treatment
Explore the safety profile and dose-PK relationship of utreloxastat for ALS
Gao L, Giannousis P, Thoolen M, et al. Clin Pharmacol Drug Dev. 2022;0:1–11. Online ahead of print.
Utreloxastat is an investigational drug currently in development for ALS.
Once registered, you will be able to view the abstract and be provided with the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-ALS-2300001 | February 2023
Sign in or register to access exclusive content on this site